Calendario›ELTX›ELI-002 2P · AMPLIFY-201
ELI-002 2P · AMPLIFY-201
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Ensayo de Elicio Therapeutics, Inc. en Minimal Residual Disease · KRAS G12D · KRAS G12R · NRAS G12D · NRAS G12R · Pancreatic Ductal Adenocarcinoma · Colorectal Cancer · Non-small Cell Lung Cancer · Ovarian Cancer · Cholangiocarcinoma · Bile Duct Cancer · Gallbladder Carcinoma (del registro, en inglés).
Más ensayos de: Adenocarcinoma ductal de páncreas · Cáncer colorrectal · Cáncer de pulmón no microcítico · Cáncer de ovario · Colangiocarcinoma.
Lo que ha anunciado la empresa
La empresa anunció que NO alcanzó su objetivo principal…of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026 • While Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic ductal adenocarcinoma…
En un 8-K del 13 ago 2026, en una frase que nombra «ELI-002». El documento en la SEC.
La empresa anunció que NO alcanzó su objetivo principal…06x15xxeltxxxph2re.htm EX-99.1 Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer • AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population. • Randomization balanced most prognostic factors between arms. However, the ELI-002 7P arm had a higher proportion of R1 resected (higher…
En un 8-K del 15 jun 2026, en una frase que nombra «ELI-002». El documento en la SEC.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 25
- Centros
- 10
- Fin del objetivo primario
- ene 2023
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en oct 2021.
Qué mide
The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002 (Adverse events were collected through 28 days after the last dose) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.
Más ensayos de ELTX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| ELI-002 7P · AMPLIFY-7P | Fase 1/2 | En marcha, sin reclutar | abr 2026 (real) |
| ELI-002 7P · AMPLIFY-EAP | no aplica | Ya no disponible | sin fecha |
Todos los de ELTX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04853017), actualizada en ago 2025.